Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings, Inc..
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at UBS Group AG.
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]